10x Genomics, Inc. 8-K

What Happened
10x Genomics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company issued a press release with those results on February 12, 2026, and furnished that press release as Exhibit 99.1 to an 8-K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Filing date: February 12, 2026 (8-K furnished to the SEC).
• Reporting period: Fourth quarter and full year ended December 31, 2025.
• Disclosure vehicle: Press release attached as Exhibit 99.1 to the Form 8-K.
• Form signed by Randy Wu, General Counsel and Secretary, on behalf of the company.

Why It Matters
This 8-K notifies investors that 10x Genomics has released its latest earnings and performance metrics for Q4 and FY2025. Investors should review the attached press release for concrete figures (revenue, net income or loss, EPS, cash flow, and any forward guidance) because those details can affect valuation and near-term trading. The filing itself does not provide the numbers in the 8-K text—see Exhibit 99.1 for the full results.